Persius/hicric huggingface dataset:
Male pseudohermaphroditism due to 17-beta-hydroxysteroid dehydrogenase deficiency
Male pseudohermaphroditism due to 17-beta-hydroxysteroid dehydrogenase deficiency is a deficiency of 17-beta-hydroxysteroid dehydrogenase isozyme 3 which leads to male pseudohermaphroditism, a condition characterized by incomplete differentiation of male genitalia in 46XY males. It is caused by mutations in the HSD17B3 gene.

# Etiology
17-beta-hydroxysteroid dehydrogenase deficiency type 3 (17HSD3) is a disorder in testosterone biosynthesis. As a consequence of this disorder, normal male sexual differentiation in impaired and hypovirilization occurs (less male sexual characteristics).

# Clinical characteristics
17-beta-hydroxysteroid dehydrogenase deficiency-3 is clinically characterized by either ambiguous external genitalia or complete female external genitalia at birth as a consequence of impaired male sexual differentiation in 46,XY individuals. Further investigations on ambiguous genitalia will eventually lead to findings of intersexuality. Severe hypovirilization (absence of male differentiation) can lead to development of female external genitalia. These females (!) are often discovered when there is absence of menarche (first menstruation) and when they begin to virilize during puberty (slowly become more like a man; deepening of the voice, acne, male musculature etc). At careful examination, testis can often be found in the inguinal channel.

# Biochemically
17-beta-hydroxysteroid dehydrogenase deficiency-3 is biochemically characterized by decreased levels of testosterone and increased levels of androstenedione as a result of the defect in conversion of androstenedione into testosterone. This leads to clinically important higher ratio of androstenedione to testosterone (A'dion/T).-

# Genetics
17-beta-hydroxysteroid dehydrogenase deficiency-3 is caused by gene mutations found in the 17BHSD3 gene. 17-beta-hydroxysteroid dehydrogenase deficiency-3 is an autosomal recessive disorder.
Electrophysiology study and ablation discharge instructions (patient information)

# Overview
Intracardiac electrophysiology study (EPS) is a test to look at the heart's electrical function. It allows doctors to check for abnormal heartbeats or heart rhythms.
Ablate means "to destroy." Cardiac ablation is a procedure that is used to destroy small areas in your heart that may be causing your heart rhythm problems.
During the procedure, small wires called electrodes are placed inside your heart to measure your heart's electrical activity. These electrodes may also be used to destroy the bad areas of your heart.
Pressure to reduce bleeding is put on the area where the catheters were inserted into your body. You will be kept in bed for at least 1 hour, and maybe up to 5 or 6 hours. Your heart rhythm will be monitored during this time.
Your doctor will decide whether you can go home on the same day or if you will need to stay in the hospital overnight to continue monitoring your heart. You will need someone to drive you home after your procedure
For 2 or 3 days after your procedure, you may have these symptoms:
- You may feel tired.
- Your chest may feel achy.
- You may notice skipped heartbeats, or times when your heartbeat is very fast or irregular.
Your doctor may keep you on your medicines, or give you new ones that help control your heart rhythm.

# When could I drive after the procedure?
You should not drive after the procedure without asking your doctor when you could do that. This is different for everyone.

# What medications should I take after the procedure?
Ask your doctor whether you should go back to taking the medications you were on before the procedure. Be sure your doctor knows about everything you are taking.

# Should I take any OTC pain medications?
You may take acetaminophen (Tylenol) every six hours as needed for pain in the area where the catheter was placed.  Please be sure you are not taking more than one product containing acetaminophen, and do not take more Tylenol than what is recommended on the label.

# When may I resume my regular activities?
You may resume your regular activities one week after the procedure. Avoid lifting, pushing, or pulling anything heavier than 10 pounds in the first week after the procedure. Also avoid any exercise that causes you to hold your breath and bear down with your abdominal muscles. Begin your exercise program one week after the procedure at half your usual routine, then gradually work back to your full routine. Please ask your doctor about your exercise instructions.

# When can I go back to work?
It depends on the type of your work. You can ask your doctor when you can go back to work.

# Follow-up care
You will be informed about your follow-up appointments before leaving the hospital.

# When to seek urgent medical care?
Call your doctor if:
- Your wound looks infected (redness, increased drainage, swelling, painful).
- You feel dizzy or short of breath.
- You have chest pain.
- You have hiccups that do not go away.
- You were unconscious for a moment.

# Sources
Guidelines for the management of cerebral vasospasm and DCI associated with aSAH

# 2012 AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage

## Management of Cerebral Vasospasm and DCI After aSAH: Recommendations
It should be noted that this agent has been shown to improve neuroogical outcomes but not cerebral vasospasm. The value of other calcium antagonists, whether administered orally or intravenously, remains uncertain.
The Living Guidelines: Pregnant patients: Polling Results for CLASS I Guidelines

# Class I Guidelines
1. Digoxin, a beta blocker, or a non dihydropyridine calcium channel antagonist is recommended to control the rate of ventricular response in pregnant patients with AF. (Level of Evidence: C) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 1 for pregnant patients with acute myocardial infarction should be:
2. Direct-current cardioversion is recommended in pregnant patients who become hemodynamically unstable due to AF. (Level of Evidence: C) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 2 for pregnant patients with acute myocardial infarction should be:
3. Protection against thromboembolism is recommended throughout pregnancy for all patients with AF (except those with lone AF and/or low thromboembolic risk). Therapy (anticoagulant or aspirin) should be chosen according to the stage of pregnancy. (Level of Evidence: C) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 3 for pregnant patients with acute myocardial infarction should be:
Unclassified Class III recommendations in guidelines for cardiovascular medicine

# Overview
Unclassified LOE is noted when the guideline does not report the level of evidence. The total number of class III recommendations with unclassified LOE in guidelines published by American cardiology societies is 21.

# Class III Recommendations with Unclassified Level of Evidence: Organized by Guideline Keywords
The table shown below is a list of class III recommendations with unclassified level of evidence obtained from American guidelines for cardiovascular medicine. The list is organized by guideline name/keywords in alphabetical order. Alternatively, to view the same list organized by year of guideline publication, click here.

# Class III Recommendations with Unclassified Level of Evidence: Organized by Year of Guideline Publication
The table shown below is a list of class III recommendations with unclassified level of evidence obtained from American guidelines for cardiovascular medicine. The list is organized by guideline year of guideline publication (newest to oldest). Alternatively, to view the same list organized by guideline name/keywords, click here.
Azithromycin And Coronary Events Study In Patients With Stable Coronary Disease

# Complete Title of Study
None reported

# Study Acronym (The trial's abbreviation if there is one)
None reported

# Principal Investigator, Co-investigators, and Collaborating Institutions
None reported

# Overview of Trial
None reported

# Disease State(s) Studied (e.g. acute MI, breast cancer, etc.)
None reported

# Study Phase (e.g. Phase I,II,III,IV) Study Phases are defined here
None reported

# Study Design (e.g. multicenter, randomized, double blind, placebo controlled)
None reported

# Study Arms and How They Were Treated (Intervention) (Explanation here)
None reported

# Primary Pre-Specified Endpoint
None reported

# Secondary Endpoints
None reported

# Inclusion Criteria
None reported

# Exclusion Criteria
None reported

# Outcome: Primary endpoint (Report both relative risk reduction and absolute risk reduction as well as number needed to treat if available)
None reported

# Outcome: Secondary endpoint (Report both relative risk reduction and absolute risk reduction as well as number needed to treat if available)
None reported

# Outcome: Exploratory endpoints (Report both relative risk reduction and absolute risk reduction as well as number needed to treat if available)
None reported

# Outcome: Safety endpoints (Report both relative risk and absolute risk as well as number needed to harm if available)
None reported

# Conclusions of the Investigators (Quote the investigators conclusions here)
None reported

# Commentary, Discussion and Limitations of the Trial (Anyone can add comments)
None reported

# Slides
None reported

# Video Commentary
None reported

# References (How to insert a reference)
None reported

# External sites for further information (How to insert links)
None reported

# Detailed information about the trial

# Ages
__ years to ___ years

# Gender (Indicate whether men, women or both were enrolled)
None reported

# Accepts Healthy Volunteers (Answer yes or no)
None reported

# Enrollment Period (Study start and end date)
None reported

# Recruitment Status (explanation)
None reported

# Enrollment (Total number of patients enrolled)
None reported

# Study Sponsor (e.g. Investigator initiated or company name)
None reported (this may not have yet been ascertained)

# Source of Data (Where is this data on this page coming from: publication, principal investigator, or co-investigator)
None reported
The content of the clinical trial wiki consists of fields that have been suggested by the World Health Organization and wwww.clinicaltrials.gov.
AHA, ASA guidelines for the management of spontaneous intracerebral hemorrhage

# 2015 AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage

## Emergency Diagnosis and Assessment: Recommendations

## Hemostasis and Coagulopathy, Antiplatelet Agents, and DVT Prophylaxis: Recommendations

### Patients with a severe coagulation factor deficiency or severe thrombocytopenia

### Patients with ICH whose INR is elevated because of VKA

### Patients with ICH who are taking dabigatran, rivaroxaban, or apixaban

### Reverse heparin in patients with acute ICH

### Patients with a history of anti platelet and ICH

### Hematoma expansion

### prevention of venous thromboembolism

### ICH patients with symptom- atic DVT or PE

## BP-Lowering: Recommendations

### ICH patients presenting with SBP between 150 and 220 mmHg

### ICH patients presenting with SBP >220 mmHg

## General Monitoring and Nursing Care: Recommendation

## Glucose Management: Recommendation

## Temperature Management: Recommendation

## Seizures and Antiseizure Drugs: Recommendations

## Management of Medical Complications: Recommendations

## ICP Monitoring and Treatment: Recommendations

## IVH: Recommendations

## Surgical Treatment of ICH: Recommendations

## Outcome Prediction and Withdrawal of Technological Support: Recommendation
Bannayan-Riley-Ruvalcaba syndrome natural history, complications and prognosis

# Overview
The symptoms of BRRS usually develop in the first decade of life.The prognosis is unknown for Bannayan-Riley-Ruvalcaba syndrome (BRRS).

# Natural History, Complications, and Prognosis
Natural History
- The symptoms of BRRS usually develop in the first decade of life, and start with symptoms such as developmental delay, macrocephaly and penile lentigines.
Complications
- Common complications of Bannayan-Riley-Ruvalcaba syndrome (BRRS) include:
Increased risk of following cancers:
Thyroid cancer: Mostly commonly follicular, very rarely papillary, but never medullary thyroid cancer
Breast cancer
Renal cell cancer
Granulosa cell tumor of the ovary
- Increased risk of following cancers:
Thyroid cancer: Mostly commonly follicular, very rarely papillary, but never medullary thyroid cancer
Breast cancer
Renal cell cancer
Granulosa cell tumor of the ovary
- Thyroid cancer: Mostly commonly follicular, very rarely papillary, but never medullary thyroid cancer
- Breast cancer
- Renal cell cancer
- Granulosa cell tumor of the ovary
Prognosis
- The prognosis is unknown for Bannayan-Riley-Ruvalcaba syndrome (BRRS).
Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study
CAPRICORN = Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study

# Overview
A multicenter, multinational, double-blind, randomized, placebo-controlled trial that enrolled 1,959 patients who had an acute MI and a left ventricular ejection fraction of <40%.
It was not known whether beta blockers confer additional benefit when used in the context of modern post-MI management (eg, fibrinolytic therapy and primary percutaneous transluminal coronary angioplasty, aspirin, and angiotensin converting enzyme inhibitors).
Patients in CAPRICORN were treated with a maximum dose of 25 mg bid and observed until 633 validated primary end points had occurred. Because the overall mortality was lower than had been predicted, a co-primary end point was adopted that included the original primary end point (all-cause mortality) plus the first of the prespecified secondary end points (all-cause mortality or cardiovascular hospitalizations).
A significant 23% reduction in the original primary end point of all-cause mortality was observed. A total of 340 (35%) patients died or had a cardiovascular hospitalization in the carvedilol group versus 367 (37%) in the placebo group. Therefore, the revised primary end point of all-cause mortality or cardiovascular hospitalization was reduced by 8%, which was not statistically significant.
Significant reductions in cardiovascular mortality, nonfatal MI, and the combination of all-cause mortality or nonfatal MI were observed.
Although statistical significance for the revised primary end point was not reached, CAPRICORN has an important role in guiding future use of beta blockers in the early post-MI period.

# Reference
-  Colucci WS. Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN)Am J Cardiol. 2004 May 6;93(9A):13B-6B.Click here to read
Risk stratification in the patient with unstable angina or non ST elevation MI

# Definition
- Unstable angina: acute ischemic symptoms, with or without EKG changes (ST depression/transient ST elevation/new T wave inversion), and absence of troponin or CK-MB elevation.
- Non ST elevation MI: acute ischemic symptoms, with or without EKG changes (ST depression/transient ST elevation/new T wave inversion), and presence of troponin or CK-MB elevation.

# Risk stratification in patient with UA/NSTEMI
- The Thrombolysis in Myocardial Infarction (TIMI) risk score for UA/NSTEMI:
The TIMI risk score for STEMI was created from simple arithmetic sum of independent predictors of mortality weighted according to the adjusted odds ratios from logistic regression analysis.
The patient pool (n=1957) came from the TIMI 11B trial.
The TIMI risk score was subsequently validated using the unfractionated heparin group from the ESSENCE trial and the enoxaparin groups from both the TIMI 11B and the ESSENCE trials.
TIMI risk score of 0-2 = low risk, TIMI risk score of 3-4 = moderate risk, TIMI risk score of 5-7 = high risk.
- The TIMI risk score for STEMI was created from simple arithmetic sum of independent predictors of mortality weighted according to the adjusted odds ratios from logistic regression analysis.
- The patient pool (n=1957) came from the TIMI 11B trial.
- The TIMI risk score was subsequently validated using the unfractionated heparin group from the ESSENCE trial and the enoxaparin groups from both the TIMI 11B and the ESSENCE trials.
- TIMI risk score of 0-2 = low risk, TIMI risk score of 3-4 = moderate risk, TIMI risk score of 5-7 = high risk.
- ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention:
The guideline defined high risk as elevated cardiac enzymes, ST segment depression, recurrent angina, hemodynamic instability, sustained VT/VF, history of DM, prior PCI in the past 6 months or CABG.
- The guideline defined high risk as elevated cardiac enzymes, ST segment depression, recurrent angina, hemodynamic instability, sustained VT/VF, history of DM, prior PCI in the past 6 months or CABG.

# Early invasive strategy vs non-invasive strategy
- TACTICS-TIMI 18: In patients with UA/NSTEMI who was treated with tirofiban, the use of early invasive strategy reduce the rate of the primary end point (death, non-fatal MI, and rehospitalization for ACS at 6 months) from 19.4% to 15.9%.
Texas Tech University Health Sciences Center School of Pharmacy Abilene Campus
Texas Tech University Health Sciences Center School of Pharmacy Abilene Campus opened on August 12, 2007. Classes are held in a Spanish-themed 36,000 square-foot building, constructed at a cost of US$15.5 million. The initial enrollment of 40 is expected to grow to 160 by fall of 2011. Also, by that time, the school is expected to have 40 professors and staff.

# Degree offered
The Texas Tech University Health Sciences Center School of Pharmacy Abilene Campus offers a single professional degree, the Doctorate of Pharmacy.

# Reference

# External link
- School of Pharmacy Expansion
Hepatology, Gallbladder, and Biliary Tract Diseases Project Mission Statement

# WikiDoc Oncology Project  Mission Statement
- Thank you for your interest in the WikiDoc Hepatology, Gallbladder, and Biliary Tract Diseases Project.
- The project aims to integrate current body of medical literature into treatment strategies for non-infectious, non-oncologic hepatic, gallbladder, and bilary tract diseases, in conformity with practice guidelines, consensus statements, systematic reviews, and expert opinions.
- Educational content provided herein is not intended to supplant but supplement clinical judgment.
- Please let us know if there is additional information you would like to see included.  We welcome your comments at this email address.
AHA/ASA guideline recommendations for prevention of stroke in women overview

# Overview
The incidence of stroke, especially in women, is fast-rising.  Stroke is the third leading cause of death in women and fifth in men.  Many studies have documented the fact that women are more adversely affected by stroke and its complications, in terms of functional recovery, quality of life when compared to men.  Therefore, it is important to provide guidelines to identify high-risk women for stroke, and also to provide recommendations regarding prevention  of stroke.

# Epidemioloogy and Dermographics

### Ischemic Stroke
In general, women have a lower incidence of ischemic stroke than men. Women have a longer life expectancy than men, therefore, at ages 85 years and older, women have a higher or similar incidences of stroke with men. A population-based incidence study also noted a 2-fold increase in stroke incidence among blacks and Hispanics when compared with whites.

### Hemorrhagic Stroke
There is an increased prevalence of subarachnoid hemorrhage in women, which has been linked to an increased prevalence of cerebral aneurysms.  Conversely, the incidence of intracerebral hemorrhage, in most cases, has been reported to be lower in women when compared with men.  The highest incidence of ICH was also observed among the black population as compared with hispanics and white population.

# Risk Factors
Adapted from AHA/ASA guideline recommendations for prevention of stroke in women (2014)
Clinical event adjudication: Peripheral arterial revascularization procedure
For the list of clinical event adjudication definitions, click here

# Peripheral arterial revascularization procedure
This chapter presents peripheral arterial revascularization procedure definitions used in the Clinical Event Committee adjudication processes. These definitions are current as of 3/26/10.

# 1. Definition of Peripheral Arterial Revascularization Procedure
A peripheral arterial revascularization procedure is a catheter-based or open surgical procedure designed to improve peripheral arterial blood flow.  This procedure may include thrombectomy, embolectomy, aneurysm/dissection repair, angioplasty, and stent placement.The intention to perform percutaneous peripheral arterial intervention is denoted by the insertion of a guidewire through a guide catheter into a peripheral artery.The target vessel(s) should be specified (e.g., carotid, vertebral, aorta, renal, iliac, femoral) and recorded as well as the type of revascularization procedure (e.g., surgical, angioplasty, stent placement, thromboembolectomy, aneurysm repair).

# 2. Procedural Success
In the case of percutaneous intervention for obstructive lesions, procedural success is defined as the achievement of a final residual diameter stenosis < 30% by angiography at the end of the procedure without any in-hospital major adverse events (death, acute onset of limb ischemia, need for urgent/emergent vascular surgery).  The balloon inflation and/or stent placement may be preceded by device activation (e.g., angiojet, directional or rotational atherectomy, lasers).

# 3. Elective and Non-elective Procedures
Elective: An elective procedure is one that is scheduled and is performed on a patient with stable peripheral arterial disease.
Non-elective: A non-elective procedure is one that is performed immediately upon diagnosis because of urgency of the medical condition (e.g., acute limb ischemia, acute stroke, acute aortic dissection, acute aneurysm rupture).

# 4. Target Vessel
A target vessel is any vessel (e.g., carotid, peripheral artery, mesenteric/renal artery) that contains the target lesion treated with the study device.  The target vessel includes the target lesion as well as segments of the vessel that are upstream and downstream to the target lesion, including side branches (native vessel).

# 5. Non-target Vessel
A non-target vessel is one for which revascularization is not attempted or one is which revascularization is performed using a non-study device.